Li Y - Search Results

1

Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.

Tong Z, Narayanan R, Atsriku C, Nissel J, Li Y, Liu H, Wang X, Surapaneni S. Tong Z, et al. Among authors: li y. Xenobiotica. 2019 Jan;49(1):54-70. doi: 10.1080/00498254.2018.1424377. Epub 2018 Jan 17. Xenobiotica. 2019. PMID: 29297772

2

Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans.

Tong Z, Atsriku C, Yerramilli U, Wang X, Nissel J, Li Y, Surapaneni S. Tong Z, et al. Among authors: li y. Xenobiotica. 2019 Jan;49(1):43-53. doi: 10.1080/00498254.2017.1413718. Epub 2017 Dec 19. Xenobiotica. 2019. PMID: 29206565

3

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans.

Tong Z, Atsriku C, Yerramilli U, Wang X, Li Y, Reyes J, Fan B, Yang H, Hoffmann M, Surapaneni S. Tong Z, et al. Among authors: li y. Xenobiotica. 2019 Feb;49(2):200-210. doi: 10.1080/00498254.2018.1425511. Epub 2018 Jan 22. Xenobiotica. 2019. PMID: 29320949

4

Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.

Kasserra C, Assaf M, Hoffmann M, Li Y, Liu L, Wang X, Kumar G, Palmisano M. Kasserra C, et al. Among authors: li y. J Clin Pharmacol. 2015 Feb;55(2):168-78. doi: 10.1002/jcph.384. Epub 2014 Sep 7. J Clin Pharmacol. 2015. PMID: 25159194 Clinical Trial.

5

Population pharmacokinetics of pomalidomide.

Li Y, Xu Y, Liu L, Wang X, Palmisano M, Zhou S. Li Y, et al. J Clin Pharmacol. 2015 May;55(5):563-72. doi: 10.1002/jcph.455. Epub 2015 Feb 4. J Clin Pharmacol. 2015. PMID: 25556560 Free PMC article.

6

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S. Li Y, et al. Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017. Clin Pharmacol. 2017. PMID: 29184451 Free PMC article.

7

Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.

Li Y, Ramírez-Valle F, Xue Y, Ventura JI, Gouedard O, Mei J, Takeshita K, Palmisano M, Zhou S. Li Y, et al. J Clin Pharmacol. 2017 Oct;57(10):1279-1289. doi: 10.1002/jcph.923. Epub 2017 May 19. J Clin Pharmacol. 2017. PMID: 28543084 Free PMC article. Clinical Trial.

8

Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers.

Li Y, Zhou S, Hoffmann M, Kumar G, Palmisano M. Li Y, et al. J Pharmacol Exp Ther. 2014 Aug;350(2):265-72. doi: 10.1124/jpet.114.215251. Epub 2014 May 15. J Pharmacol Exp Ther. 2014. PMID: 24833703

9

Exposure-response analysis to assess the concentration-QTc relationship of CC-122.

Li Y, Carayannopoulos LN, Thomas M, Palmisano M, Zhou S. Li Y, et al. Clin Pharmacol. 2016 Sep 9;8:117-25. doi: 10.2147/CPAA.S111867. eCollection 2016. Clin Pharmacol. 2016. PMID: 27672344 Free PMC article.

10

Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.

Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Chen N, et al. Among authors: li y. J Clin Pharmacol. 2014 Oct;54(10):1097-107. doi: 10.1002/jcph.304. Epub 2014 Apr 9. J Clin Pharmacol. 2014. PMID: 24719309 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240,258 results

Search Page

Filters